Literature DB >> 8418241

A pilot study of pi-class glutathione S-transferase expression in breast cancer: correlation with estrogen receptor expression and prognosis in node-negative breast cancer.

L Gilbert1, L J Elwood, M Merino, S Masood, R Barnes, S M Steinberg, D F Lazarous, L Pierce, T d'Angelo, J A Moscow.   

Abstract

PURPOSE AND METHODS: Previous studies have indicated that RNA levels for pi-class glutathione S-transferase (GST pi), a phase II, drug-metabolizing enzyme, were inversely related to estrogen receptor (ER) and progesterone receptor (PR) levels in human breast tumors. Because GST pi also is expressed in normal breast epithelium, an immunohistochemical assay that uses affinity-purified polyclonal antibodies to GST pi was developed to examine the possible relationship between GST pi expression in breast cancer cells and hormone receptor expression, as well as prognosis, in patients with primary breast cancer.
RESULTS: A strong inverse correlation between GST pi expression and ER (two-sided P [P2] = .002) and PR status (P2 = .023) was found in our study of 189 patients with primary breast cancer. GST pi expression was not related to tumor size, nodal metastasis, nuclear grade, histology, or age of the patient. In node-negative breast cancer (n = 72), increased GST pi expression was associated with decreased disease-free survival (DFS) and overall survival (OS). When GST pi expression was divided into categories of negative (no GST pi-positive tumor cells), intermediate (1% to 70% GST pi-positive tumor cells), and high (> 70% GST pi-positive tumor cells), the relative risk of tumor recurrence in patients with node-negative breast cancer was increased 3.39-fold for each successive category of expression (P2 = .0045; 95% confidence interval, 1.46 to 7.87) and the relative risk of death was increased 4.49-fold for each successive category (P2 = .0003; 95% confidence interval, 2.02 to 10.42). The actuarial 5-year OS was 100%, 79%, and 51%, and the DFS was 94%, 77%, and 44%, for the negative, intermediate, and high tumor groups, respectively. Among the factors studied in multivariate analysis (ER status, PR status, nuclear grade, and tumor size), GST pi expression was the factor that most accurately predicted shorter DFS and OS in node-negative patients.
CONCLUSION: GST pi expression is inversely related to hormone receptor status in breast cancer. This pilot study also suggests that increased GST pi expression may be an important predictor of early recurrence and death in node-negative breast cancer patients that merits additional investigation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8418241     DOI: 10.1200/JCO.1993.11.1.49

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  20 in total

1.  JS-K, a nitric oxide-releasing prodrug, induces breast cancer cell death while sparing normal mammary epithelial cells.

Authors:  Vanity McMurtry; Joseph E Saavedra; René Nieves-Alicea; Ann-Marie Simeone; Larry K Keefer; Ana M Tari
Journal:  Int J Oncol       Date:  2011-01-25       Impact factor: 5.650

2.  Transcriptional and post-transcriptional mechanisms can regulate cell-specific expression of the human Pi-class glutathione S-transferase gene.

Authors:  G J Moffat; A W McLaren; C R Wolf
Journal:  Biochem J       Date:  1997-05-15       Impact factor: 3.857

3.  Glutathione S-transferase expression in malignant mesothelioma and non-neoplastic mesothelium: an immunohistochemical study.

Authors:  K Segers; S Kumar-Singh; J Weyler; J Bogers; M Ramael; J Van Meerbeeck; E Van Marck
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

4.  Role of glutathione-S-transferase and codon 72 of P53 genotypes in epithelial ovarian cancer patients.

Authors:  Elaine Cristina Morari; Andre Bacellar Costa Lima; Natassia Elena Bufalo; Janaina Luisa Leite; Fabiana Granja; Laura Sterian Ward
Journal:  J Cancer Res Clin Oncol       Date:  2006-05-19       Impact factor: 4.553

5.  Predicting the clinical status of human breast cancer by using gene expression profiles.

Authors:  M West; C Blanchette; H Dressman; E Huang; S Ishida; R Spang; H Zuzan; J A Olson; J R Marks; J R Nevins
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-18       Impact factor: 11.205

6.  Human osteosarcoma xenografts and their sensitivity to chemotherapy.

Authors:  Skjalg Bruheim; Oyvind S Bruland; Knut Breistol; Gunhild M Maelandsmo; Oystein Fodstad
Journal:  Pathol Oncol Res       Date:  2004-09-25       Impact factor: 3.201

7.  DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response.

Authors:  Emelyne Dejeux; Jo Anders Rønneberg; Hiroko Solvang; Ida Bukholm; Stephanie Geisler; Turid Aas; Ivo G Gut; Anne-Lise Børresen-Dale; Per Eystein Lønning; Vessela N Kristensen; Jörg Tost
Journal:  Mol Cancer       Date:  2010-03-25       Impact factor: 27.401

8.  Phenotyping breast cancer cell lines EM-G3, HCC1937, MCF7 and MDA-MB-231 using 2-D electrophoresis and affinity chromatography for glutathione-binding proteins.

Authors:  Jana Mladkova; Miloslav Sanda; Eva Matouskova; Irena Selicharova
Journal:  BMC Cancer       Date:  2010-08-23       Impact factor: 4.430

Review 9.  Glutathione-related enzymes, glutathione and multidrug resistance.

Authors:  J A Moscow; K H Dixon
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

10.  Variability of glutathione S-transferase isoenzyme patterns in matched normal and cancer human breast tissue.

Authors:  M K Kelley; A Engqvist-Goldstein; J A Montali; J B Wheatley; D E Schmidt; L M Kauvar
Journal:  Biochem J       Date:  1994-12-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.